

PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Hereditary Angioedema Treatment Therapies

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

Patient Name:		Prescriber Name: Supervising Physician:		
		1		
Member/Subscriber Number:		Fax:	Phone:	
Date of Birth:		Office Contact:		
Group Number:		NPI:	State Lic ID:	
Address:		Address:		
City, State ZIP:		City, State ZIP:		
Primary Phone:		Specialty/facility name (if applicable):		
Drug Name and Strength:				
Directions / SIG:				
Please attach any perti		n for this patient that m estions and sign.	ay support approval. Please answer the	
Q1. What drug is being r	equested?			
Berinert	Firazyr	☐ Kalbitor	Ruconest	
Q2. What diagnosis is th	is drug being prescribed for?			
☐ Hereditary angioede	ma (HAE)			
Other (please specify	· · · ·			
Q3. Please provide IC	D code(s) for diagnosis.			
Q4. Which type of reques	st is this?			
☐ Continuation (please	provide start date)			
	, ,			
	tional documentation that may be	_	chart notes, labs, anticipated attack st and medical director during the prior	
I			· · · · · · · · · · · · · · · · · · ·	



PRIOR AUTHORIZATION REQUEST FORM

EOC ID:

Hereditary Angioedema Treatment Therapies

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

-	Prescriber Name: Supervising Physician:				
Patient Name:					
Q6. For CONTINUATION, please supply clinical document date of attack and number of doses utilized.	ation of acute HAE attack(s) requiring treatment including				
Q7. Please select the prescriber's specialty.					
☐ Allergist					
☐ Immunology Specialist					
☐ Hematologist					
☐ Other (Please Specify)					
Q8. Please indicate location of administration.					
☐ Home					
☐ Physician office (drug from office stock - buy and bill)					
☐ Physician office (MEMBER to obtain drug from PHARN	AACY with a prescription)				
☐ Other					
Q9. Will the quantity being requested result in a supply on	hand of more than two doses?				
☐ Yes (please provide chart notes confirming anticipated	attack frequency requiring treatment)				
□ No					
Q10. Is the patient using this for TREATMENT of acute HA	NE attacks?				
Yes					
☐ No (Please use form for Cinryze)					
Q11. If request is for RUCONEST, will the patient be using	it for laryngeal attacks?				
Yes					
□ No					
☐ N/A (request is not for Ruconest)					
Q12. Does the patient have a contraindication to therapy?					
☐ Yes ☐ No					
Q13. Is the patient using any medications know to cause a	ngioedema (i.e. ACE inhibitor, ARB, or estrogen)?				
☐ Yes (please explain) ☐ No					



PRIOR AUTHORIZATION REQUEST FORM EOC ID:

Hereditary Angioedema Treatment Therapies

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. **Please note any information left blank or illegible may delay the review process.**

		Prescriber Name:		
Patient Name:		Supervising Physician:		
Q14. Will the reque	sted drug be the only medication	on prescribed for treatment of	acute attacks?	
☐ Yes	☐ No			
Q15. Does the patie	ent have failure or, intolerance	to, or contraindication to any o	f the following?	
☐ Berinert	☐ Firazyr	☐ Kalbitor	Ruconest	
Q16. Additional Cor	mments			
Prescriber Signature			Date	
	Troodisor dignature		Date	
	By checking this box and sign the life or health of the enrollee		g the standard review timeframe may ain maximum function	
			providers may speak to the SWHP medical cision on a request before coverage has beer	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document